ATXN3 and Spinocerebellar ataxia type 3: The expression of mATXN3 in the MJD models used in this work was also evaluated via Western blotting (using antibodies against ATXN3 and polyQ expansions higher than 37 glutamines; Figures S1C,D, S5 and S6A).